We Are Crinetics


Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Read the Latest


EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

Ernst & Young LLP announces that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner.

Crinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees.

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company